Intra-Cellular Therapies Revenue and Competitors
Estimated Revenue & Valuation
- Intra-Cellular Therapies's estimated annual revenue is currently $70.6M per year.
- Intra-Cellular Therapies received $150.0M in venture funding in September 2017.
- Intra-Cellular Therapies's estimated revenue per employee is $130,481
- Intra-Cellular Therapies's total funding is $674.1M.
- Intra-Cellular Therapies's current valuation is $3.5B. (January 2022)
Employee Data
- Intra-Cellular Therapies has 541 Employees.
- Intra-Cellular Therapies grew their employee count by 14% last year.
Intra-Cellular Therapies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 61 | 7% | N/A | N/A |
#2 | $354.3M | 461 | -2% | $567.1M | N/A |
#3 | $377.1M | 1876 | -1% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $5.4M | 27 | 0% | N/A | N/A |
#6 | $45M | 224 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -82% | N/A | N/A |
#8 | $9.2M | 46 | 12% | N/A | N/A |
#9 | N/A | 694 | 46% | N/A | N/A |
#10 | $15.5M | 77 | 5% | N/A | N/A |
What Is Intra-Cellular Therapies?
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities: https://www.linkedin.com/jobs/search/keywords=intra-cellular%20therapies&location=United%20States&locationId=us%3A0
keywords:Biotechnology,Healthcare,Pharmaceuticals
$674.1M
Total Funding
541
Number of Employees
$70.6M
Revenue (est)
14%
Employee Growth %
$3.5B
Valuation
N/A
Accelerator
Intra-Cellular Therapies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, Chairman & CEO | Reveal Email/Phone |
2 | SVP Finance & Chief Financial Officer | Reveal Email/Phone |
3 | Regional Business Manager | Reveal Email/Phone |
4 | Senior Director, Market Access | Reveal Email/Phone |
5 | VP Corporate Communications/Investor Relations | Reveal Email/Phone |
6 | Neuroscience Sales Specialist | Reveal Email/Phone |
7 | Neuroscience Sales Specialist | Reveal Email/Phone |
8 | Neuroscience Sales Specialist | Reveal Email/Phone |
9 | Neuroscience Sales Specialist | Reveal Email/Phone |
10 | neuroscience Sales Specialist | Reveal Email/Phone |
Intra-Cellular Therapies News
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the...
Piper Sandler had initiated Intra-Cellular Therapies (NASDAQ:ITCI) with a hold rating saying that the current share price reflects...
NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the...
It may be almost the end of the year, but the FDA’s stamina for approvals has persevered. On Monday, Intra-Cellular Therapies secured the regulator’s blessing for its antipsychotic drug, Caplyta, despite two late-stage schizophrenia studies that left much to be desired. But as is custom with mo ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $118.3M | 541 | 5% | N/A |
#2 | $123.7M | 541 | 9% | $102M |
#3 | $161.6M | 541 | 67% | N/A |
#4 | $94.9M | 542 | N/A | N/A |
#5 | $142.3M | 542 | 3% | N/A |
Intra-Cellular Therapies Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-02-03 | $100.2M | Undisclosed | Leerink Partners LLC | Article |
| 2014-02-06 | $115.3M | Undisclosed | Leerink Partners LLC | Article |
| 2015-03-09 | $106.5M | Undisclosed | Leerink Partners LLC | Article |
| 2015-03-13 | $121.4M | Undisclosed | Leerink Partners LLC, | Article |
| 2017-09-29 | $150.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
Intra-Cellular Therapies Executives
| Name | Title |
|---|---|
| Sharon Mates | Founder, Chairman & Chief Executive Officer |
| Lawrence Hineline | Senior Vice President of Finance & Chief Financial Officer |
| Robert Davis | SVP/Chief Scientific Officer |
| Karen Patruno Sheehy | SVP, Chief Compliance Officer |
| Mark Neumann | Executive Vice President, Chief Commercial Officer |
| Suresh Durgam | Chief Medical Officer |
| Lawrence Hineline | Senior Vice President of Finance & Chief Financial Officer |
| Juan Sanchez | VP Corporate Communications/Investor Relations |
| Michael Halstead | EVP/General Counsel |
| Robert Davis | SVP/Chief Scientific Officer |
| Michael Olchaskey | SVP/Head of Regulatory Affairs |
| Karen Patruno Sheehy | SVP, Chief Compliance Officer |
| Susan Kozauer | VP Clinical Development |
| Mark Neumann | Executive Vice President, Chief Commercial Officer |
| Katie Margules | Vice President Head of Clinical Operations |
| Tom Lapnas | Vice President, Manufacturing & Supply Chain |
| Jennifer Rinaldo | Vice President, Commercial Development and Business Strategy |
| George Rodriguez | Vice President, Sales |
| Regina Dolan Donohue | Vice President, Head of Human Resources |
| Karen Patruno Sheehy | Senior Vice President |
| Debra Marchese | Vice President, Marketing |
| Gretchen Snyder | Vice President |
| John Bardi | Senior Vice President |
| Willie Earley | Senior Vice President, Head of Clinical Development |
| Jennifer Rinaldo | Vice President, Commercial Development and Business Strategy |